U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description
Curator's Comment:: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/050443s036lbl.pdf

Bleomycin sulfate is an antineoplastic antibiotic isolated from Streptomyces verticillus. It is a mixture of glycopeptide antibiotics containing primarily Bleomycin A2 (~70%) and B2 (~30%). Bleomycin binds to DNA, inhibits DNA synthesis, and causes single strand scission of DNA in vivo and in vitro at specific base sequences.

CNS Activity

Curator's Comment:: Bleomycin does not cross the blood-brain barrier.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLEOMYCIN SULFATE

Approved Use

Bleomycin for Injection, USP should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for Injection, USP has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.

Launch Date

1.12924803E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
Primary
BLENOXANE

Approved Use

BLENOXANE should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agent:Squamous Cell Carcinoma, Lymphomas, Testicular Carcinoma, Malignant Pleural Effusion.

Launch Date

1.74355202E11
PubMed

PubMed

TitleDatePubMed
Ultrastructural study of the effect of bleomycin A2 on the nucleolus and its possibly related cytoplasmic constituents in Novikoff hepatoma cells.
1975 Feb
The effect of bleomycin A2(-Cu) on the proliferation of brain tumor cells and strained epithelial cells in vitro.
1976 Mar 20
Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.
1985 Dec 15
Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer.
1988 May
Drug-induced encephalopathy after previous ifosfamide treatment.
1988 Nov 5
Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma.
1988 Sep
Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy: a report of a case and a review of the literature.
1989
Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold.
1989 Jul
Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer.
1989 Oct
Autonomic neuropathy after treatment with cisplatin, vinblastine, and bleomycin for germ cell cancer.
1990 Feb 24
Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy.
1991 Jun
Selective loss of optic nerve beta-tubulin in vincristine-induced blindness.
1992 Aug
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
1992 Aug
[Loss of ganglion cells in the retina secondary to vincristine therapy].
1992 May
Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and nongenotoxic carcinogens.
1999 Aug
Nucleic Acid recognition by metal complexes of bleomycin.
1999 Sep 8
Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.
2000 May
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.
2002 Apr
Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity.
2002 Jun
CC-chemokine receptor 2 required for bleomycin-induced pulmonary fibrosis.
2003 Dec 21
Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice.
2003 Mar
The influence of dexamethasone on the proliferation and apoptosis of pulmonary inflammatory cells in bleomycin-induced pulmonary fibrosis in rats.
2004 Mar
Feitai, a Chinese herbal medicine, reduces transforming growth factor-beta1 and monocyte chemoattractant protein-1 expression in bleomycin-induced lung fibrosis in mice.
2005 Dec
Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis.
2005 Dec
Resveratrol alleviates bleomycin-induced lung injury in rats.
2007
Early lung injury contributes to lung fibrosis via AT1 receptor in rats.
2007 Feb
Characterization of DNA reactive and non-DNA reactive anticancer drugs by gene expression profiling.
2007 Jun 1
BMP-7 does not protect against bleomycin-induced lung or skin fibrosis.
2008
Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.
2009 Feb
Protection of bleomycin-induced fibrosis and inflammation by taurine.
2009 Jul
Epigallocatechin-3-gallate exhibits anti-fibrotic effect by attenuating bleomycin-induced glycoconjugates, lysosomal hydrolases and ultrastructural changes in rat model pulmonary fibrosis.
2009 Jul 15
Bleomycin-induced nuclear factor-kappaB activation in human bronchial epithelial cells involves the phosphorylation of glycogen synthase kinase 3beta.
2009 Jun 22
Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats.
2010 Aug
Influence of p53 expression on sensitivity of cancer cells to bleomycin.
2010 Jul-Aug
C/EBPβ-Thr217 phosphorylation signaling contributes to the development of lung injury and fibrosis in mice.
2011
Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis.
2011 Apr
Removal of reactive oxygen species-induced 3'-blocked ends by XPF-ERCC1.
2011 Nov 21
Testing chemical agents with the cytokinesis-block micronucleus cytome assay.
2012
Preventing cleavage of Mer promotes efferocytosis and suppresses acute lung injury in bleomycin treated mice.
2012 Aug 15
Thymoquinone blocks lung injury and fibrosis by attenuating bleomycin-induced oxidative stress and activation of nuclear factor Kappa-B in rats.
2012 Dec 16
The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals.
2012 Jan
Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses.
2013 May 17
Direct activation of ATM by resveratrol under oxidizing conditions.
2014
Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes.
2014 Oct 1
Protocatechuic aldehyde ameliorates experimental pulmonary fibrosis by modulating HMGB1/RAGE pathway.
2015 Feb 15
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Bleomycin can be given intramuscularly, or subcutaneously in Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease and as a single dose bolus intrapleural injection (60 units) in Malignant Pleural Effusion.
0.25 to 0.50 units/kg weekly or twice weekly (Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma, Hodgkin’s disease)
Route of Administration: Intravenous
1-200 ug/ml
Name Type Language
BLEOMYCIN
HSDB   INN   VANDF   WHO-DD  
INN  
Official Name English
BLEOMYCIN HYDROCHLORIDE [JAN]
Common Name English
BLEOMYCIN [VANDF]
Common Name English
BLENAMAX
Brand Name English
NSC-125066
Code English
BLEOMYCINS
MI  
Common Name English
BLEOMYCIN [WHO-DD]
Common Name English
BLEOMYCIN [INN]
Common Name English
BLEOMYCINS [MI]
Common Name English
BLEOMYCIN [IARC]
Common Name English
BLEOMYCIN [HSDB]
Common Name English
BLEOMYCIN HEXAL
Brand Name English
BLEO
Brand Name English
BLEOCIN
Brand Name English
BLEOMYCINS [IARC]
Common Name English
MIXTURE OF CYTOTOXIC GLYCOPEPTIDES PRODUCED BY THE GROWTH OF STREPTOMYCES VERTICILLUS
Common Name English
Classification Tree Code System Code
LIVERTOX 116
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
WHO-VATC QL01DC01
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
NCI_THESAURUS C2311
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
NDF-RT N0000180854
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
FDA ORPHAN DRUG 118498
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
FDA ORPHAN DRUG 326510
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
WHO-ATC L01DC01
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
Code System Code Type Description
DRUG CENTRAL
4742
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
LACTMED
Bleomycin
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
RXCUI
1622
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY RxNorm
EVMPD
SUB00842MIG
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
HSDB
3208
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
ChEMBL
CHEMBL3039590
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
MESH
D001761
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
EPA CompTox
11056-06-7
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
CAS
11056-06-7
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
NCI_THESAURUS
C313
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
FDA UNII
40S1VHN69B
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
MERCK INDEX
M2589
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00290
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
WIKIPEDIA
BLEOMYCIN
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
INN
2721
Created by admin on Sat Jun 26 18:20:17 UTC 2021 , Edited by admin on Sat Jun 26 18:20:17 UTC 2021
PRIMARY
All of the following components must be present:
Definition References